an oral tablet for the
treatment of adult active
psoriatic arthritis
Demonstrated efficacy in active
psoriatic
arthritis clinical trials1,8,9
-
ACR20 response at week 16 with OTEZLA 30 mg BID:
38% vs. placebo: 19%, p ≤ 0.01 (n=168 for both;
primary endpoint) -
No evidence of attenuation of efficacy on ACR20
was seen for up to 52 weeks (uncontrolled from
weeks 24–52)
Simplicity of oral dosing1†
Proven safety profile1
-
Most common adverse reactions (≥ 5%) were
diarrhea (16.7%), nausea (15.3%), and headache
(10.5%), which were mostly mild to moderate in
intensity.* Incidences of these adverse events were
higher in females than in males
* More than half of these adverse events resolved within the first 30 days.1
† OTEZLA is administered 30 mg BID after initial titration. Please consult the Product Monograph for complete dosage and administration instructions, including dose adjustments in patients with severe renal impairment (CrCl < 30 mL/min).1
ACR, American College of Rheumatology; BID, twice daily; CrCl, creatinine clearance; MOA, mechanism of action; PsA, psoriatic arthritis; PsO, psoriasis.